Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

Journal of Hepatology

Volumn 68, Issue 3, 2018, Pages 402-411

  Fraser, Hannah ^a   Martin, Natasha K ^a,b   Brummer Korvenkontio, Henrikki ^c   Carrieri, Patrizia ^d,e   Dalgard, Olav ^f,g   Dillon, John ^h   Goldberg, David ⁱ   Hutchinson, Sharon ^i,j   Jauffret Roustide, Marie ^k,l   Kåberg, Martin ^m   Matser, Amy A ^n,o   Matičič, Mojca ^p,q   Midgard, Havard ^f   Mravcik, Viktor ^r,s,t   Øvrehus, Anne ^u   Prins, Maria ^n,v   Reimer, Jens ^w,x   Robaeys, Geert ^y,z,aa   Schulte, Bernd ^x   van Santen, Daniela K ⁿ   Zimmermann, Ruth ^ab   Vickerman, Peter ^a   Hickman, Matthew ^a   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d AIX MARSEILLE UNIV   (France)

^e OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^f UNIVERSITY OF OSLO   (Norway)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ HEALTH PROTECTION SCOTLAND   (United Kingdom)

^j GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^k French Institute for Public Health Surveillance   (France)

^l EHESS Sciences   (France)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^o UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^p UNIVERSITY OF LJUBLJANA   (Slovenia)

^q UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^r National Monitoring Centre for Drugs and Drug Addiction   (Czech Republic)

^s CHARLES UNIVERSITY   (Czech Republic)

^t NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^u ODENSE UNIVERSITY HOSPITAL   (Denmark)

^v UNIVERSITY OF AMSTERDAM   (Netherlands)

^w Children's Hospital Bremen North   (Germany)

^x UNIVERSITY OF HAMBURG   (Germany)

^y DEPARTMENT OF CARDIOLOGY   (Belgium)

^z HASSELT UNIVERSITY   (Belgium)

^aa UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ab ROBERT KOCH INSTITUTE   (Germany)

more..

Author keywords

Direct acting antivirals; Hepatitis C; Opioid substitution therapy; PWID

Indexed keywords

ARTICLE; BELGIUM; CZECH REPUBLIC; DENMARK; FINLAND; GERMANY; HEALTH IMPACT ASSESSMENT; HEALTH PROGRAM; HEPATITIS C; HUMAN; INCIDENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MULTICENTER STUDY; NETHERLANDS; NORWAY; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; PRIORITY JOURNAL; SCALE UP; SCOTLAND; SLOVENIA; SWEDEN; VIRUS TRANSMISSION; CHRONIC HEPATITIS C; COMPLICATION; DISEASE TRANSMISSION; EUROPE; NEEDS ASSESSMENT; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; PROCEDURES; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; THEORETICAL MODEL;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; DISEASE TRANSMISSION, INFECTIOUS; EUROPE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MODELS, THEORETICAL; NEEDLE-EXCHANGE PROGRAMS; NEEDS ASSESSMENT; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85040817518     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.10.010     Document Type: Article

References (49)

1. Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384 (2014), 1953–1997.
2. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des, J.D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
3. Ly, K.N., Xing, J., Klevens, R.M., Jiles, R.B., Ward, J.W., Holmberg, S.D., The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156 (2012), 271–278.
4. Cowie, B., Allard, N., MacLachlan, J., O86 European responses in focus: comparing viral hepatitis and HIV related deaths in Europe 1990–2010 in the global burden of disease study 2010. J Hepatol 1 (2014), S35–S36.
5. European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction. Prevention and control of infectious diseases among people who inject drugs. 2011, European Centre for Disease Prevention and Control, Stockholm.
6. European Monitoring Centre for Drugs and Drug Addition. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. EMCDDA Insights, 23. 2016, Publications Office of the European Union, Luxembourg.
7. Turner, K.M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106 (2011), 1978–1988.
8. Van Den Berg, C., Smit, C., Van, B.G., Coutinho, R., Prins, M., Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 102 (2007), 1454–1462.
9. Vickerman, P., Martin, N., Turner, K., Hickman, M., Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107 (2012), 1984–1995.
10. Martin, N.K., Hickman, M., Hutchinson, S.J., Goldberg, D.J., Vickerman, P., Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57 (2013), S39–S45.
11. Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M., Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 54 (2011), 1137–1144.
12. Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
13. Wedemeyer, H., Duberg, A.S., Buti, M., Rosenberg, W.M., Frankova, S., Esmat, G., et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21 (2014), 60–89.
14. De Vos, A., Kretzschmar, M., Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection. Math Biosci 258 (2014), 11–18.
15. de Vos, A.S., van der Helm, J.J., Matser, A., Prins, M., Kretzschmar, M.E., Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?. Addiction 108 (2013), 1070–1081.
16. Dore, G.J., Feld, J.J., Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis 60 (2015), 1829–1836.
17. G Everson, T Tran, W Towner, M Davis, D Wyles, R Nahass, et al. Safety and efficacy of treatment with the interferon-free ribavirin-free combination of sofosbuvir+ GS-5816 for 12 weeks in treatment naive patients with genotype 1–6 HCV infection. 49th European Association for the Study of the Liver International Liver Congress (EASL 2014). London, United Kingdom; 2014.
18. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 61 (2014), 373–395.
19. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
20. Leidner, A.J., Chesson, H.W., Xu, F., Ward, J.W., Spradling, P.R., Holmberg, S.D., Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 61 (2015), 1860–1869.
21. Martin, N.K., Vickerman, P., Dore, G.J., Grebely, J., Miners, A., Cairns, J., et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol 65 (2016), 17–25.
22. Vickerman, P., Grebely, J., Dore, G.J., Sacks-Davis, R., Page, K., Thomas, D.L., et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 205 (2012), 1342–1350.
23. Martin, N.K., Vickerman, P., Hickman, M., Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 274 (2011), 58–66.
24. Zábranský, T., Mravčík, V., Chomynová, P., Overall mortality of drug users in the Czech Republic. EMCDDA, (eds.), 1st ed., 2009, ResAd ResAd/EMCDDA, Prague/Lisbon.
25. Zabransky, T., Mravcik, V., Korcisova, B., Rehak, V., Hepatitis C virus infection among injecting drug users in the Czech Republic–prevalence and associated factors. Eur Addict Res 12 (2006), 151–160.
26. H Švůgerová. Spotřeba injekčního materiálu klienty pražských harm reduction služeb v závislosti na vzorcích užívání (Consumption of material for injection clients of Prague harm reduction services depending on use patterns): PhD Thesis, Clinic of Addictology of the 1st Faculty of Medicine and General Teaching Hospital in Prague (11–00611), Prague; 2015.
27. Briggs, A., Claxton, K., Sculpher, M., Decision modelling for health economic evaluation. Gray, A., Briggs, A., (eds.) Handbooks in Health Economic Evaluation Series, 2006, Oxford University Press, Oxford.
28. European Centre for Disease Prevention and Control. Hepatitis C surveillance in Europe – 2013. 2015, European Centre for Disease Prevention and Control, Stockholm.
29. Jones, H.E., Hickman, M., Welton, N.J., De Angelis, D., Harris, R.J., Ades, A., Recapture or precapture? Fallibility of standard capture-recapture methods in the presence of referrals between sources. Am J Epidemiol, 2014, kwu056.
30. Palmateer, N.E., Taylor, A., Goldberg, D.J., Munro, A., Aitken, C., Shepherd, S.J., et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One, 9, 2014, e104515.
31. Grebely, J., Mauss, S., Brown, A., Bronowicki, J.-P., Puoti, M., Wyles, D., et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials. Clin Infect Dis 63 (2016), 1405–1411.
32. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., et al. Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 165 (2016), 625–634.
33. Sacks-Davis, R., McBryde, E., Grebely, J., Hellard, M., Vickerman, P., Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. J R Soc Interface, 12, 2015, 20141197.
34. Mehta, S.H., Cox, A., Hoover, D.R., Wang, X.-H., Mao, Q., Ray, S., et al. Protection against persistence of hepatitis C. Lancet 359 (2002), 1478–1483.
35. Grebely, J., Prins, M., Hellard, M., Cox, A.L., Osburn, W.O., Lauer, G., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12 (2012), 408–414.
36. Micallef, J., Macdonald, V., Jauncey, M., Amin, J., Rawlinson, W., Van Beek, I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 14 (2007), 413–418.
37. Aitken, C.K., Lewis, J., Tracy, S.L., Spelman, T., Bowden, D.S., Bharadwaj, M., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48 (2008), 1746–1752.
38. Simmons, B., Saleem, J., Hill, A., Riley, R.D., Cooke, G.S., Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis, 2016, civ948.
39. Alavi, M., Spelman, T., Matthews, G.V., Haber, P.S., Day, C., van Beek, I., et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Int J Drug Policy 26 (2015), 976–983.
40. Duberg, A.S., Blach, S., Falconer, K., Kaberg, M., Razavi, H., Aleman, S., The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol 50 (2015), 233–244.
41. Razavi, H., Waked, I., Sarrazin, C., Myers, R., Idilman, R., Calinas, F., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21 (2014), 34–59.
42. Harris, R., Thomas, B., Griffiths, J., Costella, A., Chapman, R., Ramsay, M., et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenario. J Hepatol 61 (2014), 530–537.
43. Mullhaupt, B., Bruggmann, P., Bihl, F., Blach, S., Lavanchy, D., Razavi, H., et al. Modeling the health and economic burden of hepatitis C virus in Switzerland. PLoS One, 10, 2015, 13.
44. Innes, H., Goldberg, D., Dillon, J., Hutchinson, S.J., Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. Gut 64 (2015), 1800–1809.
45. Martin, N.K., Foster, G.R., Vilar, J., Ryder, S., Cramp, M.E., Gordon, F., et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat 22 (2015), 399–408.
46. V Mravčík, C P., G K., N V., G L., K L., et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2013 [Annual Report on Drug Situation 2013 – Czech Republic], MRAVČÍK V.2014, Praha: Úřad vlády České republiky.
47. Reitox National Focal Point. Report on the drug situation 2013 of the republic of Slovenia, Drev A.2013, Ljubljana.
48. van Santen, D.K., de Vos, A.S., Matser, A., Willemse, S.B., Lindenburg, K., Kretzschmar, M.E., et al. Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands. PLoS One, 11, 2016, e0163488.
49. Micallef, J.M., Kaldor, J.M., Dore, G.J., Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13 (2006), 34–41.